John Crown, BCh, BAO, BSc, MD, MBA, discusses the role of eribulin mesylate in triple-negative breast cancer.
John Crown, BCh, BAO, BSc, MD, MBA, professor and consultant, medical oncology, St. Vincent’s Private Hospital, Dublin, Ireland, discusses the role of eribulin mesylate (Halaven) in triple-negative breast cancer.
Multiple randomized trials have established eribulin as an active treatment for patients with TNBC, Crown says.
Moreover, the drug provides an overall survival (OS) benefit compared with standard chemotherapy for heavily pretreated patients with metastatic disease, explains Crown.
Notably, findings from a subgroup analysis of a phase 3 trial demonstrated superior OS with eribulin compared with capecitabine (Xeloda) among patients with HER2-negative tumors, including HER2-negative breast cancer and TNBC, Crown says.
As such, eribulin appears to have established itself as a potent agent in the TNBC armamentarium, concludes Crown.